Treatment of PYMT tumor-bearing mice with (1) vehicle for alpelisib and vehicle for PTX + IgG, (2) alpelisib (50 mg/kg) + PTX (10 mg/kg) + IgG, (3) vehicles + ICI (200 ug anti-PD-1 and 100 ug anti-CTLA-4), or (4) alpelisib + PTX + ICI was initiated when the tumors were ~125 mm3, and continued for 2 weeks. The gene discussed is CTLA4; the disease is neoplasm.